Roche is set to introduce its three next-generation SARS-CoV-2 rapid antigen tests (‘2.0’) for self-test and professional use in countries that accept the CE Mark.
The tests include the SARS-CoV-2 Rapid Antigen Test 2.0, the SARS-CoV-2 Rapid Antigen Test 2.0 Nasal for professional use, and the SARS-CoV-2 Antigen Self Test Nasal for self-test.
They feature improved performance, with the addition of new digital data sharing capabilities and an enhanced capture antibody.
